BC Extra | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when...
BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill. There are no therapies approved...
BC Innovations | Feb 11, 2019
Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies identified a peptide agonist of MAS receptor that could help treat vascular dementia. The compound consists of the first six residues of angiotensin(1-7) - an endogenous peptide ligand of the MAS receptor...
BC Innovations | Aug 10, 2018
Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
BC Innovations | Jan 25, 2018
Translation in Brief

No TNFα for transplants

A University of Toronto team has shown that inhibiting TNFα enhances the engraftment success of hematopoietic stem cell transplants in mice and plans to test the strategy in the clinic using Enbrel etanercept within a...
BC Week In Review | Jan 27, 2017
Clinical News

TXA127 regulatory update

FDA granted rare pediatric disease designation to TXA127 from Tarix to treat recessive dystrophic epidermolysis bullosa (RDEB). TXA127, a formulation of the angiotensin (1-7) peptide, a MAS receptor agonist, also has Orphan Drug designation for...
BC Week In Review | Sep 5, 2016
Clinical News

Sarconeos: Phase I started

Biophytis began the double-blind, placebo-controlled, dose-escalation, Belgian Phase I SARA-PK trial of Sarconeos. The first part will evaluate single doses of Sarconeos in 32 elder and young healthy volunteers, and the second part will test...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
BC Extra | Feb 22, 2012
Company News

Lanthio, Tarix in pulmonary deal

Lanthio Pharma B.V. (Groningen, the Netherlands) granted Tarix Pharmaceuticals Ltd. (Brookline, Mass.) exclusive, worldwide rights to its lanthionine-Ang(1-7) peptide . According to Lanthio, the preclinical product targets the MAS receptor and is being developed for acute...
BC Week In Review | Feb 20, 2012
Company News

Lanthio Pharma, Tarix deal

Lanthio granted Tarix exclusive, worldwide rights to its lanthionine-Ang(1-7) peptide . According to Lanthio, the preclinical product targets the MAS receptor and is being developed for acute lung injury and related indications. Lanthio is eligible for...
Items per page:
1 - 10 of 11